

From: [REDACTED]
Sent: 05 September 2006 17:00
To: Emily Marschke
Subject: Bowel Cancer UK Response to NICE

Emily,

Please find below the joint appeal by Bowel Cancer UK and CancerBackup re the NICE verdict on the CRC treatments Avastin and Erbitux.

This is a perverse decision in light of the evidence submitted. Both these treatments have proven benefits to CRC patients in the advanced stages of the disease - Avastin in first line and Erbitux in third line treatment of the disease (not second as the NICE appraisal incorrectly claims), benefits that are still being explored and increased by clinicians.

Patients who have the potential to benefit from these treatments should be allowed to receive them and those who have responded to them should be allowed to continue to receive them. In the case of both treatments, there are also no other licensed alternatives for CRC patients.

Cheers.

[REDACTED]
[REDACTED]
Director of Press, PR and Public Affairs
Bowel Cancer UK: the new name for Colon Cancer Concern (CCC)

Tel: 020 7381 9711
[REDACTED]
[REDACTED]

Address: 7 Rickett Street, London, SW6 1RU
Website: www.bowelcanceruk.org.uk
Bowel Cancer Advisory Service: 08708 50 60 50

Bowel cancer is the second most common cause of cancer death in the UK.

We are a voluntary organisation relying on donations to fund our work. Visit the website for further information.

Delivered via MessageLabs
